Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan
  
Vertex Mobile
Vertex shares are up 35% so far this year, making it one of the sector's top mid-sized performers. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cell Therapies

More from Therapy Areas